Physician profile
Marta D Eule
NPI 1407007495
$90,555.33
in general payments reported to CMS, 2019-2025
9 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $38.19 · 2023: $124 · 2024: $35K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Travel and Lodging: $1,318 · Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,707.69 |
| Travel and Lodging | $1,317.98 |
| Food and Beverage | $348.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $90,057.09 | 2024-2025 | Omnipod, Omnipod |
| Beta Bionics, INC. | $161.96 | 2024 | Ilet Bionic Pancreas |
| Zealand Pharma US, INC. | $128.40 | 2021 | |
| Abbott Laboratories | $55.80 | 2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $48.37 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $35.86 | 2021-2022 | |
| Dexcom, INC. | $27.45 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $23.44 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Eule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.